On October 02, 2017, Arbutus Biopharma Corporation, an industry-leading hepatitis B virus (HBV) therapeutic solutions company, entered into a share purchase agreement with Roivant Sciences Inc. for the sale of convertible preferred shares for gross proceeds of $116.4 million. Arbutus intends to use the proceeds to further develop and advance its clinical and preclinical HBV pipeline programs.

Farris partners Hector Mackay-Dunn, Q.C. and Ron Murray advised Arbutus on the strategic investment. Ron Chin, Robert Veitch and Jeff Hart also assisted in the transaction.

For the complete press release, click here.